评论“ApoE 靶向疗法快速清除β-淀粉样蛋白并逆转 AD 小鼠模型的缺陷”。
Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models".
机构信息
Department of Environmental and Occupational Health, University of Pittsburgh, 100 Technology Drive, Pittsburgh, PA 15219, USA.
出版信息
Science. 2013 May 24;340(6135):924-c. doi: 10.1126/science.1235809.
Abstract
Cramer et al. (Reports, 23 March 2012, p. 1503; published online 9 February 2012) demonstrated in a mouse model for Alzheimer's disease (AD) that treatment of APP/PS1ΔE9 mice with bexarotene decreased Aβ pathology and ameliorated memory deficits. We confirm the reversal of memory deficits in APP/PS1ΔE9 mice expressing human APOE3 or APOE4 to the levels of their nontransgenic controls and the significant decrease of interstitial fluid Aβ, but not the effects on amyloid deposition.
摘要
克拉默等人（2012 年 3 月 23 日，第 1503 页；网上公布于 2012 年 2 月 9 日）在阿尔茨海默病（AD）的小鼠模型中证明，用贝沙罗汀治疗 APP/PS1ΔE9 小鼠可减少 Aβ 病理并改善记忆缺陷。我们证实了 APP/PS1ΔE9 小鼠中人类 APOE3 或 APOE4 的表达逆转了记忆缺陷，使其达到非转基因对照的水平，并且显著减少了脑间质液中的 Aβ，但对淀粉样蛋白沉积没有影响。
相似文献
1
Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models".评论“ApoE 靶向疗法快速清除β-淀粉样蛋白并逆转 AD 小鼠模型的缺陷”。
Science. 2013 May 24;340(6135):924-c. doi: 10.1126/science.1235809.
2
Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models".评论“ApoE 导向疗法迅速清除β-淀粉样蛋白并逆转 AD 小鼠模型的缺陷”。
Science. 2013 May 24;340(6135):924-d. doi: 10.1126/science.1234089.
3
Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models".评论“ApoE 靶向疗法快速清除β-淀粉样蛋白并逆转 AD 小鼠模型的缺陷”。
Science. 2013 May 24;340(6135):924-f. doi: 10.1126/science.1235505.
4
Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models".评论“载脂蛋白 E 靶向治疗迅速清除 β-淀粉样蛋白并逆转 AD 小鼠模型的缺陷”。
Science. 2013 May 24;340(6135):924-e. doi: 10.1126/science.1233937.
5
Response to comments on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models".对“载脂蛋白 E 靶向治疗迅速清除β-淀粉样蛋白并逆转 AD 小鼠模型的缺陷”一文的评论的回应。
Science. 2013 May 24;340(6135):924-g. doi: 10.1126/science.1234114.
6
ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models.载脂蛋白 E 靶向治疗能迅速清除β-淀粉样蛋白并逆转 AD 小鼠模型的缺陷。
Science. 2012 Mar 23;335(6075):1503-6. doi: 10.1126/science.1217697. Epub 2012 Feb 9.
7
ABCA1 is Necessary for Bexarotene-Mediated Clearance of Soluble Amyloid Beta from the Hippocampus of APP/PS1 Mice.ABCA1 对于贝沙罗汀介导的 APP/PS1 小鼠海马中可溶性淀粉样β的清除是必需的。
J Neuroimmune Pharmacol. 2016 Mar;11(1):61-72. doi: 10.1007/s11481-015-9627-8. Epub 2015 Jul 15.
8
Medicine. Old drug, new hope for Alzheimer's disease.医学。旧药，为阿尔茨海默病带来新希望。
Science. 2012 Mar 23;335(6075):1447-8. doi: 10.1126/science.1220725.
9
Reversal of apoE4-driven brain pathology and behavioral deficits by bexarotene.倍他罗汀逆转载脂蛋白 E4 驱动的脑病理和行为缺陷。
J Neurosci. 2014 May 21;34(21):7293-301. doi: 10.1523/JNEUROSCI.5198-13.2014.
10
Modulation of Alzheimer-like synaptic and cholinergic deficits in transgenic mice by human apolipoprotein E depends on isoform, aging, and overexpression of amyloid beta peptides but not on plaque formation.人载脂蛋白E对转基因小鼠中阿尔茨海默病样突触和胆碱能缺陷的调节作用取决于亚型、衰老以及β淀粉样肽的过表达，而与斑块形成无关。
J Neurosci. 2002 Dec 15;22(24):10539-48. doi: 10.1523/JNEUROSCI.22-24-10539.2002.
引用本文的文献
1
Decoding the Effects of Bexarotene treatment on brain of AD-like model mice: Single-Cell Transcriptomics and Chromatin Accessibility Analysis.解码贝沙罗汀治疗对阿尔茨海默病样模型小鼠大脑的影响：单细胞转录组学和染色质可及性分析。
Res Sq. 2025 Aug 13:rs.3.rs-7201032. doi: 10.21203/rs.3.rs-7201032/v1.
2
BRF110, an Orally Active Nurr1-RXRα-Selective Rexinoid, Enhances BDNF Expression without Elevating Triglycerides.BRF110，一种口服活性的Nurr1-RXRα选择性类视黄醇X受体激动剂，可增强脑源性神经营养因子（BDNF）的表达而不升高甘油三酯。
J Med Chem. 2025 Feb 27;68(4):4763-4786. doi: 10.1021/acs.jmedchem.4c03046. Epub 2025 Feb 13.
3
LXR agonism for CNS diseases: promises and challenges.激动 LXR 治疗中枢神经系统疾病：前景与挑战。
J Neuroinflammation. 2024 Apr 16;21(1):97. doi: 10.1186/s12974-024-03056-0.
4
A novel apoE-mimetic increases brain apoE levels, reduces Aβ pathology and improves memory when treated before onset of pathology in male mice that express APOE3.一种新型载脂蛋白 E 模拟物可增加脑内载脂蛋白 E 水平，减少 Aβ 病理，并改善表达 APOE3 的雄性小鼠在病理发生前开始治疗时的记忆功能。
Alzheimers Res Ther. 2023 Dec 15;15(1):216. doi: 10.1186/s13195-023-01353-z.
5
Cancer drugs with high repositioning potential for Alzheimer's disease.具有高重新定位潜力的癌症药物可用于治疗阿尔茨海默病。
Expert Opin Emerg Drugs. 2023 Dec;28(4):311-332. doi: 10.1080/14728214.2023.2296079. Epub 2023 Dec 26.
6
Remembering your A, B, C's: Alzheimer's disease and ABCA1.牢记基础知识：阿尔茨海默病与ABCA1
Acta Pharm Sin B. 2022 Mar;12(3):995-1018. doi: 10.1016/j.apsb.2022.01.011. Epub 2022 Jan 24.
7
Connecting the Dots Between Hypercholesterolemia and Alzheimer's Disease: A Potential Mechanism Based on 27-Hydroxycholesterol.高胆固醇血症与阿尔茨海默病之间的联系：基于27-羟基胆固醇的潜在机制
Front Neurosci. 2022 Apr 7;16:842814. doi: 10.3389/fnins.2022.842814. eCollection 2022.
8
Some Candidate Drugs for Pharmacotherapy of Alzheimer's Disease.一些用于阿尔茨海默病药物治疗的候选药物。
Pharmaceuticals (Basel). 2021 May 13;14(5):458. doi: 10.3390/ph14050458.
9
Bexarotene Impairs Cognition and Produces Hypothyroidism in a Mouse Model of Down Syndrome and Alzheimer's Disease.贝沙罗汀在唐氏综合征和阿尔茨海默病小鼠模型中损害认知并导致甲状腺功能减退。
Front Pharmacol. 2021 Apr 15;12:613211. doi: 10.3389/fphar.2021.613211. eCollection 2021.
10
Cancer Chemotherapy Related Cognitive Impairment and the Impact of the Alzheimer's Disease Risk Factor .癌症化疗相关认知障碍及阿尔茨海默病危险因素的影响
Cancers (Basel). 2020 Dec 19;12(12):3842. doi: 10.3390/cancers12123842.
本文引用的文献
1
Abca1 deficiency affects Alzheimer's disease-like phenotype in human ApoE4 but not in ApoE3-targeted replacement mice.ABCA1 缺乏症影响载脂蛋白 E4 人类似阿尔茨海默病表型，但不影响载脂蛋白 E3 靶向替代小鼠。
J Neurosci. 2012 Sep 19;32(38):13125-36. doi: 10.1523/JNEUROSCI.1937-12.2012.
2
ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models.载脂蛋白 E 靶向治疗能迅速清除β-淀粉样蛋白并逆转 AD 小鼠模型的缺陷。
Science. 2012 Mar 23;335(6075):1503-6. doi: 10.1126/science.1217697. Epub 2012 Feb 9.
3
Apolipoprotein E in Alzheimer's disease and other neurological disorders.载脂蛋白 E 在阿尔茨海默病和其他神经紊乱中的作用。
Lancet Neurol. 2011 Mar;10(3):241-52. doi: 10.1016/S1474-4422(10)70325-2.
4
Apolipoprotein A-I deficiency increases cerebral amyloid angiopathy and cognitive deficits in APP/PS1DeltaE9 mice.载脂蛋白 A-I 缺乏症可增加 APP/PS1DeltaE9 小鼠的脑淀粉样血管病和认知缺陷。
J Biol Chem. 2010 Nov 19;285(47):36945-57. doi: 10.1074/jbc.M110.127738. Epub 2010 Aug 25.
5
Liver X receptor agonist treatment ameliorates amyloid pathology and memory deficits caused by high-fat diet in APP23 mice.肝 X 受体激动剂治疗可改善 APP23 小鼠高脂饮食引起的淀粉样蛋白病理和记忆缺陷。
J Neurosci. 2010 May 19;30(20):6862-72. doi: 10.1523/JNEUROSCI.1051-10.2010.
6
The role of ATP-binding cassette transporter A1 in Alzheimer's disease and neurodegeneration.ATP结合盒转运蛋白A1在阿尔茨海默病和神经退行性变中的作用。
Biochim Biophys Acta. 2010 Aug;1801(8):824-30. doi: 10.1016/j.bbalip.2010.02.010. Epub 2010 Feb 24.
7
The role of apolipoprotein E in Alzheimer's disease.载脂蛋白E在阿尔茨海默病中的作用。
Neuron. 2009 Aug 13;63(3):287-303. doi: 10.1016/j.neuron.2009.06.026.
8
Memory deficits in APP23/Abca1+/- mice correlate with the level of Aβ oligomers.APP23/Abca1+/- 小鼠的记忆缺陷与 Aβ 寡聚物的水平相关。
ASN Neuro. 2009 Apr 30;1(2):e00006. doi: 10.1042/AN20090015.
9
ApoE promotes the proteolytic degradation of Abeta.载脂蛋白E促进β淀粉样蛋白的蛋白水解降解。
Neuron. 2008 Jun 12;58(5):681-93. doi: 10.1016/j.neuron.2008.04.010.
10
Role of LXR and ABCA1 in the pathogenesis of Alzheimer's disease - implications for a new therapeutic approach.肝脏X受体和ATP结合盒转运蛋白A1在阿尔茨海默病发病机制中的作用——对一种新治疗方法的启示
Curr Alzheimer Res. 2007 Apr;4(2):171-8. doi: 10.2174/156720507780362227.
Zotero 插件